Interstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study

This pilot study demonstrates that replacing 16 to 26 liters of blood plasma in patients with mild cognitive impairment and Alzheimer's biomarkers with plasma from young, healthy donors is a safe and feasible procedure, supporting further investigation into its potential to delay cognitive deterioration through interstitial fluid rejuvenation.

The Gist

The Big Idea: Swapping the "Soup" of the Body

Imagine your body is like a giant, complex garden. The plants (your organs and cells) are growing in a specific type of soil and water mixture called interstitial fluid. This fluid surrounds every cell, delivering nutrients and taking away waste.

As we get older, this "soil" gets polluted with old, worn-out chemicals and loses the fresh nutrients it needs. Scientists have long known from experiments with mice that if you connect an old mouse to a young mouse, the old mouse gets healthier because it gets a taste of the young mouse's fresh blood.

This study asked a big question: Can we do something similar for humans?

Instead of connecting two people together, the researchers tried a "plasma exchange." Think of it like this:

1. Draining the old: They took a large amount of the patient's old blood plasma (the liquid part of blood) out of their body.
2. Refilling with fresh: They replaced it with fresh plasma from very young, healthy donors (ages 18–24).

The goal was to "rejuvenate" the garden soil by washing out the old, toxic ingredients and replacing them with fresh, young ones.

What They Did (The Pilot Study)

This was a pilot study, which means it was a small "test run" to see if the idea was safe and possible before trying it on a huge scale.

• The Participants: They recruited 12 people who had been recently diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer's disease. These are people who have memory issues but can still take care of themselves.
• The Donors: They found young, healthy volunteers (18–24 years old) to donate their plasma.
• The Process: The patients went through different versions of the treatment:
  • The "Intensive" Group: These patients had a lot of plasma swapped out quickly (over about 3–4 weeks), like a deep, rapid cleaning.
  • The "Less Intensive" Group: These patients had the same total amount swapped, but spread out over a much longer time (months), like a slow, steady drip.
  • The "Mixed" Group: A few patients started with very small doses to test the waters before moving to bigger doses.

In total, they swapped between 16 and 26 liters of plasma for each patient. That is a lot of liquid!

Was It Safe? (The Safety Check)

The most important question for a first-time experiment is: Did it hurt anyone?

• The Verdict: Yes, the procedure was safe and feasible.
• The "Scary" Events: Two patients had serious health events (one got a severe infection and heart rhythm issue; another was found to have a rare cancer). However, the doctors carefully reviewed these cases and decided it was very unlikely that the plasma treatment caused them. They were likely just bad luck or pre-existing conditions.
• The "Nuisance" Events: Some patients had mild reactions, like feeling dizzy, having a mild allergic reaction (hives), or feeling cold. These are common side effects of any blood procedure and were easily managed.
• Burden on Patients: The treatment took a lot of time (sitting in a chair for hours), but the patients reported that the burden was actually quite low. They were motivated and handled the process well.

Did It Work? (The Results)

Because this was a small safety test, the researchers did not claim that the treatment cured Alzheimer's or stopped memory loss. They were just checking if they could do it without hurting people.

However, they did look at some early signs:

• Cognitive Tests: They tested memory and thinking skills before and after. Two patients with the lowest starting scores got worse (which is common in this disease), but the study couldn't tell if the treatment helped or not yet.
• Physical Tests: They measured things like grip strength and lung capacity. These are signs of how "old" a body feels. They collected this data to see if it could be used in bigger future studies.
• Brain Scans: They took MRI pictures of the brain to look at blood flow and size. Again, this was just to see if the machines could capture the data, not to prove the treatment worked.

The Bottom Line

Think of this study as a proof of concept.

Before you build a massive bridge, you first build a small model to see if the materials hold up. This study built the model. The researchers proved that:

1. You can safely swap large amounts of old blood plasma with young donor plasma in elderly people with memory issues.
2. The logistics (finding donors, running the machines, managing patients) work.
3. It is safe enough to try a bigger, more serious experiment later.

What they did NOT say: They did not say this is a cure for Alzheimer's. They did not say everyone should do this. They simply said, "We tried this new way of cleaning the body's fluid, and it didn't break anything. Now we can plan a bigger test to see if it actually helps people think better."

Technical Summary

1. Problem Statement

• Scientific Context: Heterochronic parabiosis (connecting the circulatory systems of young and old animals) has been shown to reverse age-related physiological decline and improve cognitive function in rodents. This is attributed to the removal of "aged" plasma factors and the introduction of "young" factors.
• Clinical Gap: While the AMBAR trial demonstrated that removing patient plasma and replacing it with saline/albumin (dilution only) could modestly delay cognitive decline in Alzheimer's Disease (AD), no human study has yet tested the hypothesis of simultaneously removing aged plasma and replacing it with large volumes of young donor plasma to mimic heterochronic parabiosis.
• Target Population: Patients with Mild Cognitive Impairment (MCI) with biomarker evidence of AD pathology, a group with limited disease-modifying treatment options.
• Objective: To establish the safety, feasibility, and logistical parameters of a "Interstitial Fluid Rejuvenation" protocol in humans, aiming to replace the molecular environment of organs with that of a 18–24-year-old.

2. Methodology

• Study Design: Open-label, unblinded pilot study (NCT06234436) conducted at Oslo University Hospital and Bærum Hospital, Norway.
• Participants: 12 patients diagnosed with MCI consistent with AD pathology (confirmed via PET-CT or CSF biomarkers).
  • Inclusion: MoCA score $\ge$ 17, preserved Activities of Daily Living (ADL).
  • Exclusion: Life expectancy <1 year, recent cancer, inability to consent.
• Donor Criteria: Healthy plasma donors aged 18–24 years. Donors underwent rigorous screening, including HLA and HNA antibody testing to prevent Transfusion-Related Acute Lung Injury (TRALI).
• Intervention Protocols: Three distinct treatment arms were tested to optimize the equilibration of donor plasma into the patient's interstitial fluid (~12L volume):
  1. "Pilot-Pilot" (Mixed Group, n=5): Initial low-dose ramp-up followed by varying intensities and maintenance phases to refine safety and logistics.
  2. Intensive Protocol (n=4): High-frequency exchange. 9–10 sessions over 24 days. Each session exchanged 3 bags of Fresh Frozen Plasma (FFP) (1.8L) every 2–3 days. Total volume exchanged: ~17.4L.
  3. Less Intensive/Long Duration (n=3): Lower frequency. 1 bag of FFP (~0.6L) twice weekly for 18 weeks. Total volume exchanged: ~16.1L.
• Procedure: Therapeutic Plasma Exchange (TPE) using Terumo Spectra Optia or Aurora machines. Anticoagulant: Sodium Citrate. Calcium supplementation was administered to prevent hypocalcemia.
• Outcome Measures:
  • Primary: Safety (Adverse Events) and Feasibility (completion rates, burden).
  • Secondary/Exploratory: Cognitive trajectories (MoCA, IQCODE), physiological aging markers (Grip strength, FEV1), and brain metrics (MRI hippocampal volume, cerebral blood flow).

3. Key Contributions

• Novel Protocol: This is the first human study to combine large-volume plasma removal with large-volume young donor plasma replacement, moving beyond simple dilution (saline/albumin) to active molecular replacement.
• Interstitial Rejuvenation Concept: The study operationalized the theoretical concept of "interstitial fluid rejuvenation," calculating dosing schedules based on transcapillary exchange rates (albumin/IgG equilibration) to ensure young plasma components reach tissue interstitial spaces.
• Logistical Framework: Established a viable supply chain and safety protocol for using fresh, non-quarantined young donor plasma in a clinical trial setting, including specific screening for HLA/HNA antibodies to mitigate TRALI risks.
• Multi-Modal Assessment: Integrated cognitive testing, physical frailty metrics, and advanced neuroimaging (MRI, ASL, QSM) to create a comprehensive baseline for future efficacy trials.

4. Results

• Safety & Feasibility:
  • All 12 patients completed their assigned treatment protocols with no dropouts.
  • Adverse Events (AEs):
    • Grade 4 (Life-threatening): 2 events. One severe infection/liver abscess and one malignant sarcoma diagnosis. Both were judged to have a low probability of being caused by the plasma exchange.
    • Grade 3: 6 events (mostly allergic reactions like urticaria, cough, or arrhythmia). Managed with antihistamines/corticosteroids; most treatments continued or paused briefly.
    • Grade 1-2: Common minor AEs included mild hypocalcemia, transient sleepiness, and injection site reactions.
  • Burden: Patient-rated burden (PeRBA) was lowest for the Intensive group (mean score 22.8), suggesting that despite higher frequency, the concentrated treatment period was less burdensome than the prolonged, irregular schedule of the less intensive group.
• Cognitive & Physiological Outcomes (Preliminary):
  • Cognitive Decline: Two patients with low baseline MoCA scores (17) experienced further decline. The remaining patients showed stable or slightly improved trajectories, though the study was not powered to determine efficacy.
  • Physiological Metrics: Grip strength and FEV1 were successfully tracked as markers of biological aging.
  • Neuroimaging: Hippocampal volume and cerebral blood flow were successfully measured pre- and post-treatment, validating their use as secondary endpoints.
• Cost Analysis: The intensive protocol was the most expensive (approx. €6,650/patient) primarily due to personnel costs, while the less intensive protocol was cheaper (approx. €4,541/patient).

5. Significance and Future Directions

• Proof of Concept: The study confirms that large-volume young-donor plasma exchange is safe and feasible in cognitively impaired elderly patients, supporting the transition to a larger, randomized controlled trial (RCT).
• Patient Selection Refinement: The observation that patients with very low baseline cognitive scores (MoCA < 20) continued to decline suggests that future trials should enforce stricter inclusion criteria (e.g., MoCA $\ge$ 20) to target patients where disease progression might still be modifiable.
• Therapeutic Potential: By addressing both the removal of toxic aged factors and the replenishment of beneficial young factors, this approach offers a potentially more potent mechanism for delaying AD progression than previous dilution-only strategies.
• Broader Application: The authors speculate that this "interstitial rejuvenation" protocol may be highly effective for frailty and other age-related conditions, not just cognitive decline, given the strong link between physical frailty and dementia.

Conclusion: This pilot study successfully established a safe, scalable protocol for human heterochronic plasma exchange. It provides the necessary safety data and logistical framework to justify a Phase II/III randomized trial to determine if this intervention can effectively delay cognitive decline and improve physiological aging in humans.